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ABSTRACT
Objective To determine cancer morbidity in members of
the armed forces who took part in tests of chemical
warfare agents from 1941 to 1989.
Design Historical cohort study, with cohort members
followed up to December 2004.
Data source Archive of UK government research facility at
Porton Down, UK military personnel records, and national
death and cancer records.
Participants All veterans included in the cohort study of
mortality, excluding thoseknown tohavediedor been lost
to follow-up before 1 January 1971 when the UK cancer
registration systemcommenced. 17013malemembersof
the UK armed forces who took part in tests (Porton Down
veterans) and a similar group of 16520 who did not (non-
Porton Down veterans).
Main outcome measures Cancer morbidity in each group
of veterans; rate ratios, with 95% confidence intervals,
adjusted for age group and calendar period.
Results 3457 cancers were reported in the Porton Down
veterans compared with 3380 cancers in the non-Porton
Down veterans. While overall cancer morbidity was the
same in both groups (rate ratio 1.00, 95% confidence
interval 0.95 to 1.05), Porton Down veterans had higher
rates of ill defined malignant neoplasms (1.12, 1.02 to
1.22), in situ neoplasms (1.45, 1.06 to 2.00), and those of
uncertain or unknown behaviour (1.32, 1.01 to 1.73).
Conclusion Overall cancer morbidity in Porton Down
veterans was no different from that in non-Porton Down
veterans.
INTRODUCTION
After the first world war, research conducted at the
chemical defence establishment at Porton Down
included a “human volunteer programme” and mem-
bers of the armed forces took part in experiments
studying the potential impact of chemical agents on
military capability and the effectiveness of protective
measures.1 2 Between 1941 and 1989, over 18 000
members of the armed forces were recorded as having
taken part in this programme. Over 50% of these
veterans were recorded as taking part in tests involving
chemicals that are known or probable human carcino-
gens, the most common being dermal exposures to
sulphur mustard.3While their overall cancer mortality
was similar to that of veterans who did not take part in
tests at PortonDown,4 past exposure to these chemicals
might have affected their risk of developing common
cancers with relatively good survival such as certain
skin cancers. We report here on cancer morbidity in
Porton Down veterans by studying cancers reported
for the period from 1971, when the UK cancer
registration system commenced, to 2004.
METHODS
Information provided here focuses on aspects relevant
to cancer morbidity. More details of the methods used
are provided elsewhere.4
Study population
We considered for inclusion all veterans included in
the cohort study of mortality.4 Porton Down veterans
were all male members of the British armed forces
recordedashavingparticipated in tests between1April
1941 and 31December 1989, while non-PortonDown
veterans were other similar members of the armed
forces not recorded as having taken part in tests at
Porton Down.4 We excluded veterans known to have
died or been lost to follow-up before 1 January 1971.
Follow-up
Weobtained death certificates, notifications of emigra-
tions, and data on cancers registered since 1 January
1971 from the National Health Service central
registers.4 Each condition listed on death certificates
as causing or contributing to death was coded by the
Office for National Statistics according to ICD-10
(international classification of diseases, 10th revision).
Cancer registration data for all cancers registered on or
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after 1 January 1971 were provided electronically and
includeddateof diagnosis and cancer site or type coded
according to the ICD coding system at the time of
registration (ICD-8, 9, or 10). The research team
recoded ICD-8 and ICD-9 codes to ICD-10 codes.
Classification of chemical exposures
We used contemporaneous experimental records of
tests carried out as part of the “human volunteer
programme” in the Porton Down historical archive to
retrospectively assess exposure.3 5 Data abstraction
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Fig 1 | Rate ratios for selected cancer sites or types in Porton Down veterans included in tests involving vesicants relative to all non-
Porton Down veterans, adjusted for age group and calendar period. Rate ratio estimates are represented by box with size
inversely proportional to variance. Vertical dotted line shows the estimate for any neoplasm
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involved linking, when possible, each test to an
individual veteran and the classification of that test as
involving a chemical or not. The type of chemical was
recorded as being a vesicant (blistering agent), a nerve
agent, or other chemical. There were eight specific
chemicals for which there were records of at least 1000
Porton Down veterans having been tested: three
vesicants (sulphur mustard, Lewisite, and nitrogen
mustard), one nerve agent (sarin), two lachrymators
(CS andCR), and two anti-nerve agent pharmaceutical
chemicals (pralidoxime and atropine). Two of these
chemicals have been classified by the International
Agency for Research on Cancer (IARC) as either a
known (sulphur mustard and cancer of the upper and
lower respiratory tract) or probable (nitrogen mustard
and squamous cell carcinoma of the skin) human
carcinogen.6 We also considered benzene, a chemical
classified by IARC as a leukaemogen6 and used as a
diluent in tests in 994 veterans.3
Of theveterans recordedasbeingexposed to sulphur
mustard, 74% of those in the analyses of cancer
morbidity could be classified according to cumulative
exposure. Veterans exposed to a total of ≥10.63 mg of
sulphur mustard were classified as having “high”
exposures.3 Equivalent classifications were possible
for 66% of veterans exposed to Lewisite and 75% of
those exposed to nitrogen mustard, the corresponding
“high” exposure levels being ≥13.69 mg and
≥23.73 mg, respectively.3 For 93% of tests involving
sulphur mustard, we could classify veterans according
to the biological effect recorded, equivalent figures
Table 2 | Exposure data abstracted in 17 013 Porton Down
veterans contributing to cancer morbidity analyses
No (%) of veterans
No of tests:
1 2010 (11.8)
2-5 3844 (22.6)
6-9 3523 (20.7)
10-14 2806 (16.5)
≥15 3910 (23.0)
None 920 (5.4)
Decade of first test*:
1940s 5437 (32.0)
1950s 5933 (34.9)
1960s 2230 (13.1)
1970s 1964 (11.5)
1980s 1449 (8.5)
No of chemical tests†:
≥1 15 481 (96.2)
None 612 (3.8)
Type of chemical test†:
Vesicant:
Any 9473 (58.9)
Sulphur mustard‡ 9232 (57.4)
Lewisite 1437 (8.9)
Nitrogen mustard 971 (6.0)
Nerve agent:
Any 3488 (21.7)
Sarin 2896 (18.0)
Other chemical:
Any 11 292 (70.2)
CS 1315 (8.2)
CR 1172 (7.3)
Pralidoxime 1690 (10.5)
Atropine 1552 (9.6)
Benzene 812 (5.0)
*Date of first visit for those with no test data.
†Includes 16 039 veterans for whom type of test could be determined.
‡Includes mustard sensitivity tests.
Table 1 | Characteristics of 17 013 Porton Down veterans and
16 520 non-Porton Down veterans contributing to cancer
morbidity analyses. Figures are numbers (percentages) of
veterans
Characteristic
Porton Down
veterans
Non-Porton Down
veterans
Service at enlistment:
Army 10 348 (60.8) 9976 (60.4)
Air force 3924 (23.1) 3885 (23.5)
Navy (and marines) 2741 (16.1) 2659 (16.1)
Decade of birth:
Before 1920 2988 (17.6) 3125 (18.9)
1920s 3168 (18.6) 2960 (17.9)
1930s 5942 (34.9) 5833 (35.3)
1940s or later 4915 (28.9) 4602 (27.9)
Place of birth:
England 13 440 (79.9) 12974 (79.2)
Wales 846 (5.0) 861 (5.3)
Scotland 1607 (9.6) 1673 (10.2)
Other 908 (5.4) 864 (5.3)
Age (years) at enlistment:
<16 1207 (7.1) 1192 (7.2)
16-<18 4831 (28.6) 4178 (25.3)
18-<20 6104 (36.1) 5896 (35.7)
20-<22 2081 (12.3) 2242 (13.6)
≥22 2688 (15.9) 3002 (18.2)
Period at enlistment*:
Before second world war 749 (4.4) 706 (4.3)
During secondworld war 4448 (26.3) 4347 (26.3)
After second world war 7571 (44.8) 7462 (45.2)
After national service 4143 (24.5) 3995 (24.2)
Total duration of service†:
<2 397 (2.4) 2705 (16.4)
2-<3 2761 (16.5) 3304 (20.0)
3-<4 2499 (14.9) 2480 (15.0)
5-<10 6355 (37.9) 5040 (30.5)
≥10 4755 (28.4) 2980 (18.1)
Vital state at 31 December 2004:
Alive 10 396 (61.1) 10 222 (61.9)
Deceased 6510 (38.3) 6197 (37.5)
Follow-up censored at:
Discharge from services 41 (0.2) 30 (0.2)
Emigration 17 (0.1) 20 (0.1)
Other 49 (0.3) 51 (0.3)
*Second world war dates taken as 1 September 1939 to 30 April 1945;
national service dates taken as 1 May 1945 to 31 December 1960.
†Includes 148 Porton Down veterans, and 132 non-Porton Down
veterans still serving at time of data abstraction.
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being 98% for Lewisite and 83% for nitrogen mustard.
Veterans with a least one dermal vesicle or a necrosed
area recorded after tests involving these vesicants were
classified as having had an exposure with at least one
“high”biological effect.Thederivationof these groups,
and of similar groups for nerve agent exposures, is
described elsewhere.3 For chemicals other than vesi-
cants or nerve agents, we collected information on the
number of tests recorded.
Statistical analysis
All veterans included in the previously reported
mortality analysis as alive and under follow-up on or
after 1 January 1971 contributed to the analysis. The
primarymethod involved comparing registration rates
in Porton Down veterans with those of non-Porton
Down veterans by calculating rate ratios. For each
Porton Down veteran, we counted person years of
follow-up from 1 January 1971 or the earliest
subsequent date that they were first recorded as being
included in a test. For non-Porton Down veterans, we
counted person years from the date derived by adding
to their enlistment date the time between enlistment
and first attendance at PortonDown for the veteran for
whom they had been selected. For each specific cancer
site or type, person years stopped at the earliest of date
of registration of the first cancer, death, loss to follow-
up, or 31 December 2004. For veterans lost to follow-
up, person years stopped at the last date they were
known to be alive (such as date of emigration or
discharge from the services).Whenwe compared rates
in Porton Down and non-Porton Down veterans we
included cancers identified only from the death
certificate. For cancers identified in this way, we used
the date of death as the date of cancer registration.
Rate ratios were estimated for all neoplasms
combined and according to type (malignant, in situ,
benign, uncertain or unknown behaviour). For malig-
nant neoplasms, we also estimated rate ratios sepa-
rately for 16 predetermined cancer sites or types.
Veterans withmore than one cancer of the same site or
type had only the first cancer counted while those with
cancers registered for two ormore different types (such
as primary cancers of skin and bladder) contributed a
cancer to each. We calculated person years separately
for each cancer site or type stratified according to 15
five year age groups (15-19, 20-25, etc, to ≥85) and five
year calendar periods (1971-4, 1975-9, etc, to 2000-4).
All rate ratioswere adjusted for age group and calendar
period and estimated with 95% confidence intervals,
and P values calculated, with the Mantel-Haenszel
method.7 When the number of cancers expected in
either group of veterans was less than 10, we estimated
adjusted rate ratios and tested for significance by fitting
exact conditional Poisson regression models to the
stratified data.8
We also compared rates of cancer in each group of
veterans with rates in England and Wales, using only
Table 3 | Rate ratios (95% confidence intervals) for selected cancer sites and types in Porton Down veterans relative to non-Porton Down veterans, unadjusted and
adjusted for age group and calendar period
Cancer site/type (ICD-10 code)
No of cases Rate ratio
Porton Down
veterans
Non-Porton Down
veterans Unadjusted
Adjusted
(95%CI)
Any malignant neoplasm (C00-C97) 3114 3140 0.96 0.99 (0.94 to 1.04)
Upper aerodigestive (C00-C14, C30-C32) 132 117 1.10 1.11 (0.87 to 1.43)
Oesophagus (C15) 103 115 0.87 0.89 (0.68 to 1.16)
Stomach (C16) 189 170 1.08 1.12 (0.91 to 1.38)
Intestine and rectum (C17-C20) 364 392 0.90 0.93 (0.81 to 1.07)
Pancreas (C25) 89 91 0.95 0.98 (0.73 to 1.31)
Trachea, bronchus, and lung (C33, C34) 851 782 1.06 1.09 (0.99 to 1.20)
Melanoma of skin (C43) 60 50 1.17 1.19 (0.82 to 1.74)
Other skin (C44) 436 496 0.86 0.87* (0.77 to 0.99)
Prostate (C61) 381 422 0.88 0.92 (0.80 to 1.05)
Bladder (C67) 193 202 0.93 0.97 (0.79 to 1.18)
Other urinary tract (C64-C66, C68) 65 85 0.75 0.76 (0.55 to 1.04)
Brain and other central nervous system (C71, C72) 56 66 0.83 0.83 (0.58 to 1.19)
All leukaemias (C91-C95) 74 84 0.86 0.89 (0.65 to 1.21)
Other lymphatic and haematopoietic (C81-C90, C96) 139 126 1.08 1.09 (0.86 to 1.39)
All other primary malignant neoplasms† 182 148 1.20 1.22 (0.99 to 1.52)
Ill defined, secondary, or unspecified malignant neoplasms (C76-C80) 975 878 1.08 1.12* (1.02 to 1.22)
Any in situ neoplasm (D00-D09) 93 64 1.42 1.45* (1.06 to 2.00)
Any benign neoplasm (D10-D36) 31 31 0.98 0.99 (0.60 to 1.63)
Any neoplasm of uncertain or unknown behaviour (D37-D48) 126 95 1.29 1.32* (1.01 to 1.73)
Any neoplasm (C00-C97, D00-D48) 3288 3282‡ 0.97 1.00 (0.95 to 1.05)
*P<0.05.
†C21-24, C26-C29, C37-C41, C45-C50, C60, C62, C63, C69, C70, C73-C75, C97.
‡Excludes neoplasms for four veterans for whom person years could not be calculated.
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those cancers notified from registrations. We counted
person years from the same date as that used for rate
ratio calculations but stopped at the date when the
veteran was last known to be alive in the UK. We
stratified person years of follow-up according to 15 five
year age groups (15-19, 20-24, etc, to≥85) andby single
calendar year (from 1941 to 2004). Expected registra-
tions were calculated by multiplying the person years
for each five year age group and single calendar year by
the corresponding registration rates for England and
Wales. Standardised registration ratios were estimated
from the ratio of observed to expected registrations.
We obtained 95% confidence intervals and P values
using the normal approximation to the Poisson
distribution.8
Analyses reported here relate to 17 013 Porton
Down veterans, and 16 520 non-Porton Down veter-
ans, all of whom were included in mortality analyses.4
Updating of databases after the mortality analysis
removed two Porton Down veterans and four non-
Porton Down veterans from the analysis but added
three non-Porton Down veterans. All analyses were
performed with Stata 10 (www.stata.com). All tests of
significance were two sided.
RESULTS
Of the veterans included in themortality analysis, 93%
(17 013/18 276) of Porton Down veterans and 94%
(16 520/17 600) of non-Porton Down veterans
contributed data to analyses on cancer morbidity. Of
those excluded from analyses, in over 60% of Porton
Down (796/1263) and non-Porton Down veterans
(703/1,080) this was because they had died between
1941 and 1970. Service at enlistment and other
characteristics were similar to that of non-Porton
Down veterans (table 1). As in the mortality study,
Porton Down veterans had a longer total duration of
military service. The distribution of Porton Down
veterans according to frequency, calendar period, and
type of chemical test was also similar to that reported
previously (table 2).
The number of men with one or more cancer
registrations was 3029 in Porton Down veterans and
3015 in non-Porton Down veterans. We identified a
further 530 veteranswith cancer fromdeath certificates
(259 and 271). The total number of cancers recorded in
each group was 3457 and 3380, respectively. The
percentage with two or more registrations was slightly
larger in Porton Down than non-Porton Down
veterans: 12.3% (374/3029) v 10.6% (320/3015).
Overall, rates for all neoplasmswere the same inboth
groups of veterans (rate ratio 1.00, 95% confidence
interval 0.95 to 1.05) as were those for all malignant
neoplasms (0.99, 0.94 to 1.04) (table 3). Porton Down
veterans had higher rates of ill defined, secondary, or
unspecified malignant neoplasms (1.12, 1.02 to 1.22),
in situ neoplasms (1.45, 1.06 to 2.00), and those of
uncertain or unknown behaviour (1.32, 1.01 to 1.73)
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Fig 2 | Rate ratios for selected cancer sites or types in Porton Down veterans included in tests involving nerve agents relative to all
non-Porton Down veterans, adjusted for age group and calendar period. Rate ratio estimates are represented by box with size
inversely proportional to variance. Vertical dotted line shows the estimate for any neoplasm
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and lower rates of skin cancer other than melanoma
(0.87, 0.77 to 0.99). Someneoplasms classified as in situ
or of uncertain or unknown behaviour (16 in Porton
Downand10 in non-PortonDownveterans)were non-
melanomaskincancers.Whenwecombined thesewith
malignant skin cancers other than melanoma, the rate
ratio for this cancer site increased only slightly (0.89,
0.78 to 1.01).
Rate ratios for all neoplasms and all malignant
neoplasms were just below unity for veterans exposed
to tests involving any vesicant, sulphur mustard, or
nitrogen mustard and just above unity for Lewisite
(fig 1).Veterans exposed toLewisite had rates of cancer
of the trachea, bronchus, and lung 25% higher than
non-PortonDownveterans (1.25, 1.05 to 1.48, P=0.01).
Porton Down veterans exposed to tests involving any
nerve agent, sarin, or any chemical other than nerve
agents or vesicants had rate ratios for all neoplasms and
all malignant neoplasms just below unity (figs 2 and 3).
The rate of cancer of the oesophagus was raised in
veterans exposed to CS (2.17, 1.04 to 4.52, P=0.03).
Table 4 shows results for veterans classified as having
had high levels of exposure or biological effect either for
chemicals with previous evidence of carcinogenicity
(such as sulphur mustard for cancers of the trachea,
bronchus, and lung) or where rate ratios were raised in
Porton Down veterans (such as for CS and oesophageal
cancer). When we compared the resultant estimates of
rate ratios to the results for all exposed Porton Down
veterans, in nearly all cases the estimate obtained was
loweror similar to thatobtained forallveterans.Theonly
instance where the estimate for the high exposure group
was above theupper limit of the 95%confidence interval
forall veteranswas for skincancersother thanmelanoma
in relation to high dermal exposure to nitrogenmustard
(1.59, 0.97 to 2.61, v1.13, 0.82 to 1.57). For veteranswith
a dermal vesicle recorded (high biological effect),
however, the rate ratio estimate was lower than that of
all exposed veterans (1.05, 0.59 to 1.87).
When compared with cancer registration rates in
England and Wales, rates in Porton Down veterans
were 10% lower for all neoplasms (standardised
registration ratio 0.90, 0.87 to 0.93) and 6% lower for
all malignant neoplasms (0.94, 0.91 to 0.98). Corre-
sponding results for non-Porton Down veterans were
0.87 (0.85 to 0.90) and 0.94 (0.90 to 0.97), respectively.
DISCUSSION
Overall occurrence of cancer in veteranswho took part
in tests at Porton Down was similar to that of other
veterans and lower than in the general population.
These findings are in accord with their cancer
mortality.4 We also found no evidence of an excess of
any specific, clearly defined, cancer type or site in all
Porton Down veterans combined. As expected, the
similarity to our findings for mortality was particularly
notable for highly fatal cancers such as those of the
trachea,bronchus, and lung: the9%higher ratesof lung
cancer morbidity in Porton Down veterans is identical
to the excess reported for mortality.4 In the current
study, we were particularly interested in cancers with a
relatively good survival. There was no evidence to
suggest rates of one of the commonest of these—
malignant skin cancers other than melanoma—were
higher in Porton Down veterans, even after we
reclassified neoplasms previously coded as in situ or
of uncertain or unknown behaviour. Porton Down
veterans did, however, experience increased rates of ill
defined, secondary or unspecified malignant neo-
plasms, in situ neoplasms, and neoplasms of uncertain
or unknown behaviour. Such findings are difficult to
interpret in the absence of information on smoking
habits and other risk factors for cancer.
We identified almost 500 different chemicals in the
records at Porton Down for 1941-89.3 We focused on
nine specific chemicals to which the largest numbers of
veterans were exposed. Given the large number of
outcomes and exposure groups, some of the associa-
tions found might be due to chance. Of the nine
chemicals, sulphur mustard and benzene are known
human carcinogens, while nitrogen mustard is a
probable carcinogen.6 Of these, the chemical most
often used in tests was sulphur mustard, a carcinogen
known to affect the upper and lower respiratory tract.
Table 4 | Rate ratios (95% confidence intervals) for selected cancer sites/types (ICD-10) for
Porton Down veterans with high recorded levels of exposure to specific chemicals relative to
non-Porton Down veterans, adjusted for age group and calendar period
Chemical and indicator of high exposure level No of cases Adjusted rate ratio (95% CI)
Sulphur mustard
Dermal ≥10.63 mg:
Upper aerodigestive (C00-C14, C30-C32) 26 0.91 (0.60 to 1.40)
Trachea, bronchus, and lung (C33, C34) 207 0.98 (0.84 to 1.15)
Dermal vesicle:
Upper aerodigestive (C00-C14, C30-C32) 38 1.28 (0.88 to 1.86)
Trachea, bronchus, and lung (C33, C34) 266 1.10 (0.95 to 1.27)
Lewisite
Dermal ≥13.69 mg:
Trachea, bronchus, and lung (C33, C34) 31 1.22 (0.85 to 1.75)
Other skin (C44) 11 1.17 (0.58 to 1.94)
Dermal vesicle:
Trachea, bronchus, and lung (C33, C34) 76 1.26 (0.99 to 1.59)
Other skin (C44) 21 0.85 (0.55 to 1.33)
Nitrogen mustard
Dermal ≥23.73 mg:
Other skin (C44) 17 1.59 (0.97 to 2.61)
All leukaemias (C91-C95) 1 0.47 (0.01 to 2.78)
Dermal vesicle:
Other skin (C44) 12 1.05 (0.59 to 1.87)
All leukaemias (C91-C95) 0 0.00 (0.00 to 1.74)
CS (two or more tests)
Oesophagus (C15) 5 2.73 (0.84 to 6.97)
Pralidoxime (two or more tests)
All neoplasms of uncertain or unknown behaviour
(D37-D48)
5 2.88 (0.80 to 8.42)
Atropine (two or more tests)
All neoplasms of uncertain or unknown behaviour
(D37-D48)
3 2.28 (0.45 to 7.26)
Benzene (two or more tests)
All leukaemias (C91-C95) 7 1.44 (0.55 to 3.21)
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Over half of Porton Down veterans were included in
tests involving this chemical but they experienced no
increased cancer morbidity, either overall or for any
specific cancer. This probably reflects the low cumu-
lative exposures received, especially compared with
those of manufacturing workers in whom excesses of
upper and lower respiratory cancer have been
reported.9 10 In addition, use of physical protective
barriers (such as masks and clothing), which were
recorded as used in over 30% of tests involving
vesicants,3 will have reduced the actual exposure of
veterans to these chemicals.
0.98 (0.92 to 1.04)
0.97 (0.91 to 1.03)
1.10 (0.83 to 1.47)
0.93 (0.68 to 1.27)
1.17 (0.92 to 1.49)
0.90 (0.76 to 1.07)
0.96 (0.68 to 1.36)
1.09 (0.97 to 1.22)
1.25 (0.83 to 1.88)
0.80 (0.69 to 0.94)
0.83 (0.70 to 0.98)
0.96 (0.76 to 1.21)
0.79 (0.54 to 1.14)
0.73 (0.48 to 1.12)
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1.13 (1.02 to 1.26)
1.32 (0.92 to 1.91)
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1.48 (1.10 to 2.00)
0.96 (0.78 to 1.18)
0.92 (0.74 to 1.14)
1.72 (0.80 to 3.70)
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Fig 3 | Rate ratios for selected cancer sites or types in Porton Down veterans included in tests involving chemicals other than vesicants or nerve agents relative to all
non-Porton Down veterans, adjusted for age group and calendar period. Rate ratio estimates are represented by box with size inversely proportional to variance.
Vertical dotted line shows the estimate for any neoplasm
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Despite it being a known human carcinogen, there
was no evidence of an overall excess of cancer in
veterans exposed to benzene. Previous epidemiologi-
cal evidence indicates an association between occupa-
tional exposure to benzene and leukaemia.6 Although
the rate ratio for leukaemia was above unity, the
confidence interval was wide and the rate ratio did not
increase when we restricted analysis to veterans with
twoormore tests. The increased strength of association
with skin cancer other than melanoma in veterans
recorded to have high exposure to nitrogen mustard is
noteworthy, givenpreviousevidence that this chemical
is a human carcinogen.6 This needs to be qualified,
however, by the absence of an increase in those in
whom the biological effect was high.
Althougharsenic andarsenic compounds arehuman
carcinogens,6 and Lewisite is an organic arsenic
compound, there have been no previous epidemiolo-
gical studies of the carcinogenicity of this specific
chemical.11 While there was no evidence of an overall
excess of cancer in Porton Down veterans exposed to
Lewisite, therewas an excess of lung cancer, whichwas
also present in our previous mortality analyses.4 The
lack of association with increasing exposure or effect
levels for this chemical, togetherwith the lackofdataon
a known key confounding factor (smoking), make it
difficult to attribute this excess to tests at Porton Down
and it might be a chance finding.
For the other chemicals examined, there were no
clear associations between any specific defined cancer
type or site with sarin, pralidoxime, or atropine.
For CS, while the overall cancer occurrence was
lower than in non-Porton Down veterans, it was raised
for cancer of the oesophagus, particularly in those who
had two or more tests. A similar excess was seen in
veterans exposed to CR, the other lachrymator
included in our analyses.
In summary, the overall rates of cancer morbidity in
PortonDown veterans were not raised relative to other
veterans or the general population. The excesses of ill
defined, secondary or unspecified malignant neo-
plasms, in situ neoplasms, and neoplasms of uncertain
or unknown behaviour were seen across several of the
chemical exposure groups analysed and are difficult to
interpret.
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WHAT IS ALREADY KNOWN ON THIS TOPIC
Many tests in the Porton Down research programme into
chemical warfare agents involved known carcinogens
WHAT THIS STUDY ADDS
Overall cancermorbidity was no higher inmilitary personnel
whohadbeen included in tests at PortonDown than in those
who had not been included or in the general population
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